ann out re immunoxel, page-37

thanks for balancing out the "bleak" and defamatory picture busily being painted by some and providing some background and current data that some may not wish to take on board

Will STI ultimately go "places"?

Only time will tell - which of the "promising products" will be a company maker or not and if STI will rise and shine or die a slow death

But any of these products can only be a company maker if the cash is raised to develop and promote them - and STI like a lot of other companies can only ( or up to now at least) do this via placements which means dilution

STI will also need to start to use more sound judgment on how to proceed and to implement restraint on cash burn (and possibly side-line/off-load non-core projects)

Indications are that there is considerable interest in TCM - see last India deal ann - and TCM easily can be a company maker if managed prudently

Ann re EGM must be due shortly and will hopefully contain a bit more detail and (I hope) some more forward looking statements.

And the EGM is a platform to talk to board members and raise concerns - if you are a SH exercise your rights, make phone calls and talk to people - don't rely on second and third hand information.